Edition:
United Kingdom

IP Group PLC (IPO.L)

IPO.L on London Stock Exchange

134.60GBp
19 Jan 2018
Change (% chg)

0.80 (+0.60%)
Prev Close
133.80
Open
133.40
Day's High
135.00
Day's Low
129.80
Volume
461,754
Avg. Vol
1,017,776
52-wk High
200.50
52-wk Low
109.10

Select another date:

Mon, Dec 18 2017

BRIEF-IP Group Says Autifony Therapeutics Signs 627.5 Mln Euros Collaboration Deal With Boehringer Ingelheim​

* ‍PORTFOLIO COMPANY AUTIFONY THERAPEUTICS SIGNS EUR 627.5 MILLION COLLABORATION AGREEMENT WITH BOEHRINGER INGELHEIM​ Source text for Eikon: Further company coverage:

BRIEF-IP Group ‍welcomes Touchstone Innovations' recommendation to shareholders to accept offer​

* ‍WELCOMES ANNOUNCEMENT MADE BY TOUCHSTONE INNOVATIONS PLC RECOMMENDING THAT TOUCHSTONE SHAREHOLDERS ACCEPT OFFER​

BRIEF-IP Group says Touchstone Innovations offer now unconditional

* IP GROUP PLC - ‍ACCEPTANCES IN EXCESS OF 96%; ACCEPTANCE CONDITION SATISFIED IN TOUCHSTONE INNOVATIONS DEAL​

BRIEF-UK's CMA not to refer IP Group, Touchstone Innovations deal to phase II probe

* UK'S CMA - ‍ DECIDED NOT TO REFER IP GROUP, TOUCHSTONE INNOVATIONS DEAL TO PHASE 2 INVESTIGATION Further company coverage: (Bengaluru Newsroom)

BRIEF-IP Group's Istesso announces positive outcome from P1 study

* ISTESSO ANNOUNCES POSITIVE OUTCOME FROM P1 STUDY Source text for Eikon: Further company coverage:

BRIEF-UK'S CMA says considering IP Group-Touchstone Innovations deal

* UK'S CMA SAYS CONSIDERING WHETHER OR NOT THAT ANTICIPATED ACQUISITION BY IP GROUP OF TOUCHSTONE INNOVATIONS WILL RESULT IN CREATION OF RELEVANT MERGER SITUATION (Bengaluru Newsroom: +91 80 6749 1136)

BRIEF-IP Group updates on offer for Touchstone, capital raising

* PROPOSED TRANSACTION IN FINAL STAGES OF PRE-NOTIFICATION PROCESS WITH CMA FOLLOWING WHICH FORMAL 40 BUSINESS DAY PHASE 1 REVIEW PERIOD BY CMA SHALL COMMENCE; ANTICIPATED TO OCCUR SHORTLY

BRIEF-IP Group says Istesso has started Phase 2a trial for rheumatoid arthritis drug

* Istesso commences phase 2a for mbs2320 in rheumatoid arthritis and expands research and development collaboration with Janssen

BRIEF-IP Group says Chinese investor blocked from taking stake in company

* IP Group has received confirmation from China's Beijing Galaxy World Group that they have not received necessary approvals to make investment in IP

Select another date: